Introduction The global primary sclerosing cholangitis (PSC) market is entering a phase of accelerated expansion, with its valuation rising from USD 194.3 million in 2024 and...
Introduction The US primary sclerosing cholangitis (PSC) market is poised for remarkable expansion over the next decade, driven by growing awareness, innovative therapies, and increasing prevalence...